CFO
TMO icon

CVA Family Office’s Thermo Fisher Scientific TMO Stock Holding History

CVA Family Office’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Sell
1,475
-89
-6% -$42.7K 0.07% 163
2026
Q1 		$769K Buy
1,564
+93
+6% +$50.5K 0.08% 135
2025
Q4 		$853K Buy
1,471
+6
+0.4% +$3.39K 0.1% 117
2025
Q3 		$711K Buy
1,465
+166
+13% +$77.3K 0.09% 137
2025
Q2 		$527K Sell
1,299
-231
-15% -$96.6K 0.07% 161
2025
Q1 		$761K Buy
1,530
+84
+6% +$45.5K 0.12% 116
2024
Q4 		$752K Buy
1,446
+69
+5% +$37.9K 0.12% 114
2024
Q3 		$852K Hold
1,377
– – 0.14% 104
2024
Q2 		$762K Hold
1,377
– – 0.14% 107
2024
Q1 		$800K Sell
1,377
-32
-2% -$18K 0.14% 102
2023
Q4 		$748K Sell
1,409
-69
-5% -$33.4K 0.15% 100
2023
Q3 		$748K Buy
1,478
+150
+11% +$79.9K 0.17% 97
2023
Q2 		$693K Buy
1,328
+26
+2% +$14K 0.15% 99
2023
Q1 		$750K Buy
1,302
+4
+0.3% +$2.25K 0.17% 91
2022
Q4 		$715K Sell
1,298
-114
-8% -$60.4K 0.17% 89
2022
Q3 		$716K Sell
1,412
-250
-15% -$140K 0.19% 85
2022
Q2 		$903K Buy
1,662
+345
+26% +$190K 0.25% 71
2022
Q1 		$778K Sell
1,317
-70
-5% -$40.2K 0.19% 80
2021
Q4 		$925K Buy
1,387
+528
+61% +$330K 0.23% 69
2021
Q3 		$379K Sell
859
-433
-34% -$238K 0.27% 62
2021
Q2 		$652K Buy
1,292
+128
+11% +$60.4K 0.19% 78
2021
Q1 		$531K Buy
1,164
+305
+36% +$146K 0.2% 72
2020
Q4 		$400K Hold
859
– – 0.25% 64
2020
Q3 		$379K Buy
859
+160
+23% +$66.1K 0.27% 62
2020
Q2 		$253K Buy
699
+200
+40% +$67K 0.21% 74
2020
Q1 		$142K Buy
+499
New +$157K 0.14% 90

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

CVA Family Office's TMO Position: Q2 2026 in Review

CVA Family Office reduced its Thermo Fisher Scientific (TMO) stake by 5.7% in Q2 2026, selling an estimated $42.7K and leaving 1,475 shares worth $740K. The position accounts for 0.07% of the portfolio, ranked #163.

CVA Family Office first reported a position in TMO in Q1 2020 and has held it in 26 quarters since. The position peaked at $925K in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • CVA Family Office held 1,475 shares of Thermo Fisher Scientific worth $740K as of Q2 2026.
  • CVA Family Office sold 89 Thermo Fisher Scientific shares in Q2 2026, an estimated $42.7K.
  • Thermo Fisher Scientific made up 0.07% of CVA Family Office's portfolio in Q2 2026, its #163 holding.
  • CVA Family Office first reported a position in Thermo Fisher Scientific in Q1 2020 and has held it in 26 quarters since.
  • CVA Family Office's Thermo Fisher Scientific position peaked at $925K in Q4 2021.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.